文献速递肿瘤 PET/CT

18F-氟环亮氨酸PET成像检测乳腺癌模型中的谷氨酰胺酶抑制

18F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.
PubMed 文献 · J Nucl Med · 2022-06-30

本研究在三阴性乳腺癌(TNBC)和雌激素受体阳性乳腺癌细胞及小鼠移植瘤模型中,评估18F-氟环亮氨酸PET作为谷氨酰胺酶抑制剂(GLSi)药效动力学生物标志物的潜力。结果显示,在谷氨酰胺酶活性高的TNBC模型中,CB839治疗后18F-氟环亮氨酸的分布容积(VD)显著增加,且与谷氨酰胺酶活性变化及18F-(2S,R4)-氟谷氨酰胺VD变化一致;在低谷氨酰胺酶模型中未见此变化。结论认为18F-氟环亮氨酸PET有潜力作为GLSi的临床可转化药效动力学生物标志物。

要点

  • 18F-氟环亮氨酸细胞摄取由谷氨酰胺转运体介导。
  • 在高谷氨酰胺酶活性的TNBC模型中,CB839治疗后18F-氟环亮氨酸VD显著增加。
  • 在低谷氨酰胺酶活性的TNBC或MCF-7模型中,CB839治疗后VD未见显著变化。

核心结论

  • 18F-氟环亮氨酸PET有潜力作为谷氨酰胺酶抑制剂的临床可转化药效动力学生物标志物。

研究设计与样本

  • 研究在体外用人乳腺癌细胞评估18F-氟环亮氨酸摄取,并在小鼠TNBC移植瘤(HCC38、HCC1806、MBA-MD-231)和雌激素受体阳性乳腺癌移植瘤(MCF-7)中进行动态PET成像。
  • 小鼠在基线时及经2天CB839或溶媒治疗后进行动态PET成像,通过Logan图分析估算18F-氟环亮氨酸的分布容积(VD)。
  • 为在小鼠中进行18F-氟环亮氨酸PET,示踪剂制剂中的柠檬酸盐被磷酸盐缓冲盐水替代。

主要发现

  • 细胞摄取研究表明18F-氟环亮氨酸的摄取由谷氨酰胺转运体介导。
  • 在谷氨酰胺酶活性高的TNBC模型(HCC38和HCC1806)中,CB839治疗后VD显著增加;而在谷氨酰胺酶活性低的TNBC或MCF-7模型中未见VD显著增加。
  • VD的变化与CB839对比溶媒治疗的肿瘤中谷氨酰胺酶活性变化一致,也与先前验证为细胞谷氨酰胺池大小指标的18F-(2S,R4)-氟谷氨酰胺VD变化一致。
  • 在HCC1806肿瘤中,CB839治疗后观察到18F-FDG PET信号中度但显著的降低。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aggressive cancers such as triple-negative breast cancer (TNBC) avidly metabolize glutamine as a feature of their malignant phenotype. The conversion of glutamine to glutamate by the glutaminase enzyme represents the first and rate-limiting step of this pathway and a target for drug development. Indeed, a novel glutaminase inhibitor (GLSi) has been developed and tested in clinical trials but with limited success, suggesting the potential for a biomarker to select patients who could benefit from this novel therapy. Here, we studied a nonmetabolized amino acid analog, 18F-fluciclovine, as a PET imaging biomarker for detecting the pharmacodynamic response to GLSi. Methods: Uptake of 18F-fluciclovine into human breast cancer cells was studied in the presence and absence of inhibitors of glutamine transporters and GLSi. To allow 18F-fluciclovine PET to be performed on mice, citrate in the tracer formulation is replaced by phosphate-buffered saline. Mice bearing triple-negative breast cancer (TNBC) xenografts (HCC38, HCC1806, and MBA-MD-231) and estrogen receptor-positive breast cancer xenografts (MCF-7) were imaged with dynamic PET at baseline and after a 2-d treatment of GLSi (CB839) or vehicle. Kinetic analysis suggested reversible uptake of the tracer, and the distribution volume (VD) of 18F-fluciclovine was estimated by Logan plot analysis. Results: Our data showed that cellular uptake of 18F-fluciclovine is mediated by glutamine transporters. A significant increase in VD was observed after CB839 treatment in TNBC models exhibiting high glutaminase activity (HCC38 and HCC1806) but not in TNBC or MCF-7 exhibiting low glutaminase. Changes in VD were corroborated with changes in GLS activity measured in tumors treated with CB839 versus vehicle, as well as with changes in VD of 18F-(2S,R4)-fluoroglutamine, which we previously validated as a measure of cellular glutamine pool size. A moderate, albeit significant, decrease in 18F-FDG PET signal was observed in HCC1806 tumors after CB839 treatment. Conclusion: 18F-fluciclovine PET has potential to serve as a clinically translatable pharmacodynamic biomarker of GLSi.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhou R, Choi H, Cao J, et al. 18F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models. J Nucl Med. 2022. PMID: 35772960. doi:10.2967/jnumed.122.264152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。